Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.

Nat Med · 2025 · PMC12532583 · PMID 41023484

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with HER2-altered tumors receiving TT showed a trend toward higher OS compared to the SoC arm, with an mOS of 10.2 months (95% CI: 6.5–not evaluable) versus 5.6 months (95% CI: 2.8–13.7) (HR = 0.61, 95% CI: 0.32–1.16; Fig. 4h ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.